Monday, March 25th | 18 Adar II 5779

Subscribe
January 3, 2019 10:27 am

Teva, Amgen End Dispute Over Generic Cinacalcet HCl Tablets

avatar by Reuters and Algemeiner Staff

Email a copy of "Teva, Amgen End Dispute Over Generic Cinacalcet HCl Tablets" to a friend

A Teva building in Jerusalem, Dec. 14, 2017. Photo: Reuters / Ammar Awad.

Teva Pharmaceutical Industries Ltd said on Thursday it will pay an undisclosed amount to settle an ongoing dispute with Amgen Inc over its generic Cinacalcet HCl product.

The Israel-based drugmaker has also agreed to stop selling the generic product until its license date in mid-year 2021, or earlier under certain circumstances.

Teva said it recently received approval for the generic product and launched it in the United States.

Cinacalcet hydrochloride is approved for the treatment of secondary hyperparathyroidism in adults with chronic kidney disease on dialysis and for the treatment of higher levels of calcium in adults with parathyroid carcinoma.

Share this Story: Share On Facebook Share On Twitter Email This Article

Let your voice be heard!

Join the Algemeiner

Algemeiner.com